Ipilimumab, a monoclonal antibody against CTLA4 has demonstrated promising and 31 durable anti-cancer effect. Consistent with its mechanism of action of de novo 32 stimulation or enhancement of pre-existing T cell responses, a number of immune-33 related adverse events (irAEs) have been observed in patients treated with ipilimumab.
slightly higher in patients who did not receive high dose corticosteroids, there was no 75 statistically significant difference between treatment arms.
76

Conclusion
77
Systemic high dose corticosteroid therapy in patients with ipilimumab-related 78 hypophysitis may not be indicated. Instead, supportive treatment of hypophysitis-related 79 hormone deficiencies with the corresponding hormone replacement should be given. suggested that systemic HDS do not appear to counteract the anti-cancer effects of 93 ipilimumab (13, 14) , although this has been questioned in another study (15) . To the 94 best of our knowledge, there has been no study assessing the effects of HDS on the 95 outcome of ipilimumab-related hypophysitis. In this retrospective study, we did not CCR-14-2353 studies, at 3 to 8 weeks after identification of pituitary enlargement, which did not show 218 resolution of pituitary enlargement. CI 35 to 93%) had grade 2 toxicity; 3 of 10 (30%; 95% CI 7 to 65%) had grade 3/4 235 toxicity. Toxicity rates were comparable between the HDS and non-HDS cohorts.
237
We compared the frequency of resolution and the median times to resolution, based on 238 laboratory testing data available, between those with and without systemic HDS 239 treatment ( Figure   245 1), although the data suggest that the frequency of resolution of secondary 246 hypothyroidism may be less in the HDS group (46% versus 89%, Fisher's exact p=0.07) 247 (Figure 1) . In addition, median times to resolution for each adverse event were 248 comparable between the two groups ( Table 4) .
250
During the course of the study, four of 15 (27%) patients in the HDS treatment group 251 died, whereas one of 10 (10%) patients in the group that did not receive HDS died.
252
Twelve-month Kaplan-Meier estimates (S.E.) of survival were 83% (7.7%) for the full 253 cohort, and 80% (10.8%) and 89% (10.5%) in patients who did or did not receive HDS, 254 respectively (Figure 2) . All deaths were attributed to the underlying metastatic disease. (18, 21) . In contrast, in the current study the 262 incidence of ipilimumab-related hypophysitis was found to be higher in males (Table 1) . since ACTH and TSH deficiencies were most commonly seen in these patients (Table   299 2). The recovery of corticotroph function appears to be rare, since resolution of 300 secondary adrenal insufficiency was not observed in this study and was infrequently 301 reported in previous studies (9, 10, 13). The median time to onset of pituitary Since secondary adrenal insufficiency, which can be life threatening, occurs in almost 308 every patient with ipilimumab-related hypophysitis, we recommend starting these Author Manuscript Published OnlineFirst on December 23, 2014; DOI: 10.1158 /1078 -0432.CCR-14-2353 As a result of its immunosuppressant activity, the potential effects of corticosteroids on 333 the anti-cancer activity of immune checkpoint inhibition must be taken into 334 consideration. In a previous study, the median duration of response was somewhat 335 shorter in patients who received systemic HDS, although there was no statistically 336 significant effect on the overall duration of clinical response (13). In the present study,
337
we observed an 83% one-year survival rate in the full cohort, which surpasses survival 338 rates reported in previously published trials of ipilimumab (3, 29) . A higher rate of 339 mortality was observed in the group treated with HDS; however, the distributions of 340 overall survival were not statistically significantly different between groups (Figure 2 ).
341
The survival outcomes of our study concur with those of previous studies (13, 15), The time is measured in weeks. N: Number; n/a: Not applicable. 
